Научные статьи
\
Прикладные науки. Медицина. Технология
\
Mедицинские науки
\
Фармакология. Общая терапия. Токсикология
Факторы риска гематологической токсичности и многопараметрический анализ показателей перефирической крови при лимфоме Ходжкина (часть 1): статистический анализ
Журнал: Вестник Российского научного центра рентгенорадиологии Минздрава России @vestnik-rncrr
Рубрика: Онкология
Статья в выпуске: 1 т.9, 2009 года.
Бесплатный доступ
По результатам лечения 92 больных I - IV стадии лимфомы Ходжкина по протоколу химиотерапии CEA/ABVD проведен статистический анализ основных гематологических параметров. Определены наиболее значимые показатели периферической крови, ответственные за гематологическую токсичность при проведении химиотерапии с режимом введения цитостатиков 1 раз в две недели. Выделенные интервалы представляют интерес для онкогематологов, занимающихся лекарственной терапией лимфомы Ходжкина.
Похожие статьи в разделе Фармакология. Общая терапия. Токсикология
Короткий адрес: https://sciup.org/14955160
IDS: 14955160
Risk factors hematological toxicity and multiparameter analysis of the laboratory data peripheral blood in Hodgkin's disease (part 1): the statistic analysis
Russian Scientific Roentgen Radiological Center, Rosmedtechnology, Moscow The authors have formulated approaches for hematological toxicity of the laboratory data peripheral blood of new alternating chemotherapy regimens CEA/ABVD based on the results of treatment in 92 patients I - IV stages Hodgkin's disease. Authors specified the most important factors, among statistically significant, of hematological toxicity prognosis of chemotherapy regimens CEA/ABVD with administration of the cytostatic agents once in two weeks. The factor of hematological toxicity administration colony-stimulating factors was constructed.
Текст научной статьи Факторы риска гематологической токсичности и многопараметрический анализ показателей перефирической крови при лимфоме Ходжкина (часть 1): статистический анализ
Методы
Факторы риска развития гематологической токсичности при проведении химиотерапии с режимом введения цитостатиков 1 раз в две недели Заключение
Список литературы Факторы риска гематологической токсичности и многопараметрический анализ показателей перефирической крови при лимфоме Ходжкина (часть 1): статистический анализ
- Даценко П.В., Паньшин Г.А., Сотников В.М., Мельник Ю.Д., Ивашин А.В., Подольский П.Н. Новые программы комбинированного лечения лимфомы Ходжкина.//Онкогематология-2007.-№ 4-С.27-35.
- Дворецкий М.Л. Пособие по вариационной статистике. -М: 1971.
- Иванов С.Д. Прогнозирование лейкопении на начальных этапах лучевой и химиотерапии больных лимфогранулематозом.//Вопр. онкол.-2000.-№2.-т.46.-с.129-135.
- Ивантер Э. В., Коросов А. В. Основы биометрии: Введение в статистический анализ биологических процессов и явлений. -Петрозаводск, 1992.
- Кабанов С.В. Использование пакета Statistica 5.0 для статистической обработки опытных данных: Методические указания для дипломного проектирования. -Саратов: Изд-во Саратовского гос. агр. ун-та, 2000. -С.47.
- Ballova V., Ruffer J.U., Haverkamp H., at all. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly).//Ann Oncol., 2005, v. 16(1), p. 124-31.
- Barlett N.L., Rosenberg S.A., Hoppe R.T., et all. Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: A preliminary report//J. Clin. Oncol.-1995.-v.13.-p.1080-1088.
- Brosteanu O http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Brosteanu%20O%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus , Hasenclever D http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Hasenclever%20D%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus , Loeffler M http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Loeffler%20M%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus , Diehl V http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Diehl%20V%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus . Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin's disease // Ann Hematol. javascript:AL_get(this,%20'jour',%20'Ann%20Hematol.'); 2004.- v. 83(3).- p 176-82.
- De Vita V.T., Serpick A., Carbone P. Combination chemotherapy in the treatment of advanced Hodgkin's disease//Ann. Intern. Med. -1970.-v.73-p.881-897.
- Diehl V. Современная терапия лимфомы Ходжкина.//Конференции http://doctor.lymphoma.ru/show.html?id=2> Malignant lymphoma 2, Lugano, 2005. http://doctor.lymphoma.ru/show.html?id=91>
- Diehl V., Franklin J., Hasenclever D., et all. BEACOPP: A new regimen for advanced Hodgkin's disease//Annals of Oncology.-1998.-v.9.-(Suppl.5).-p.67-71.
- Diehl V http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Diehl%20V%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus , Thomas RK http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Thomas%20RK%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus , Re D http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Re%20D%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus . Part II: Hodgkin's lymphoma--diagnosis and treatment // Lancet Oncol. javascript:AL_get(this,%20'jour',%20'Lancet%20Oncol.'); , 2004.- v5(1).- p. 19-26.
- Engel C http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Engel%20C%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus , Loeffler M http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Loeffler%20M%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus , Schmitz S http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Schmitz%20S%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus , at all. Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group (GHSG) // Ann Oncol. javascript:AL_get(this,%20'jour',%20'Ann%20Hematol.'); 2000.- v. 11(9).- p 1105-14.
- Engert A http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Engert%20A%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus ., Ballova V http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Ballova%20V%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus ., Haverkamp H http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Haverkamp%20H%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus ., at all. Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group // J Clin Oncol. javascript:AL_get(this,%20'jour',%20'J%20Clin%20Oncol.'); - 2005, v. 23(22, p. 5052-60.
- Evens A.M http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Evens%20AM%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus ., Cilley J http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Cilley%20J%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus ., Ortiz T http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Ortiz%20T%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus . et all. G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis // Br. J. Haematol. javascript:AL_get(this,%20'jour',%20'Br%20J%20Haematol.'); - 2007.- v 137(6).- p545-52.
- Franklin J., Diehl V. Dose escalated BEACOPP chemotherapy regimen for advanced stage Hodgkin's disease: final analysis of the HD9 randomized trial of the GHSG.//Ann. of Oncology.-2002.-v13.-suppl.1.-p.-98-101.
- Gilbert N., 1978. Statistiques, Montreal, Ed. HRW.
- Klimm B, Engert A. Differences in hematotoxicity between male and female patients with Hodgkin lymphoma and other malignancies//Nat Clin Pract. Oncol. , 2008.-v. 5(6)-p 316-23.
- Klimm B http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Klimm%20B%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus , Reineke T http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Reineke%20T%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus , Haverkamp H http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Haverkamp%20H%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus , at all. Role of hematotoxicity and sex in patients with Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group // J Clin Oncol. javascript:AL_get(this,%20'jour',%20'J%20Clin%20Oncol.'); , 2005 Nov 1; v. 23(31), p. 8003-11.
- Mauch P.V., Armitage J.D., Diehl V., et all. Hodgkin's disease//Philadelphia.-1999.
- Nangalia J http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Nangalia%20J%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus ., Smith H http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Smith%20H%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus ., Wimperis J.Z http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Wimperis%20JZ%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus . Isolated neutropenia during ABVD chemotherapy for Hodgkin lymphoma does not require growth factor support //Leuk javascript:AL_get(this,%20'jour',%20'Leuk%20Lymphoma.'); . Lymphoma.- 2008.- v 49(8) .-1530-6.
- Sieber M http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Sieber%20M%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus , Bredenfeld H http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Bredenfeld%20H%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus , Josting A http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Josting%20A%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus ., et. all. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group // J Clin Oncol. javascript:AL_get(this,%20'jour',%20'J%20Clin%20Oncol.'); - 2003.- v21.-suppl.9.- p.-1734-9.
- Wedgwood A http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Wedgwood%20A%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus ., Younes A http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Younes%20A%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus . Prophylactic use of filgrastim with ABVD and BEACOPP chemotherapy regimens for Hodgkin lymphoma // Clin. Lymphoma Myeloma.- javascript:AL_get(this,%20'jour',%20'Clin%20Lymphoma%20Myeloma.'); 2007.-v8 Suppl 2.- S63-6.
